GEO series
Semaglutide and exercise synergy in obesity: preserving muscle mass and uncovering organ crosstalk
GSE304862
Mus musculus
Expression profiling by high throughput sequencing
209 samples
Submitted 2026/08/07
Platform GPL24247
Summary
Background and aims: The glucagon-like peptide-1 receptor agonist semaglutide is an antidiabetic medication that has recently been approved for treatment of obesity as well. While its efficacy on weight management is well established, associated concomitant loss of muscle mass can be a potential drawback. In this study, we investigated whether combining semaglutide with exercise could enhance its metabolic effects while mitigating muscle loss. Method: Ldlr−/−.Leiden mice were fed a high fat diet (HFD) for 20 weeks to induce obesity, insulin resistance, metabolic dysfunction-associated steatohepatitis (MASH) and atherosclerosis. Mice were subsequently left untreated (control) or treated for 14 weeks with semaglutide, exercise (running wheel) or the combination thereof. Histological examination and comprehensive transcriptome analyses were conducted on white adipose tissue, muscle, liver and heart to explore underlying mechanisms. Results: Semaglutide significantly reduced fat mass (-31%) but also lean mass (-11%). Combining semaglutide with exercise further reduced fat mass (-45%) and lean mass as well but to a lesser extent (-8%). Semaglutide alone or combined with exercise significantly improved insulin sensitivity, plasma cholesterol and triglycerides. The combination of semaglutide with exercise improved , adipose tissue inflammation, liver steatosis, liver inflammation and atherosclerotic lesion area. With regard to muscle parameters, combination treatment significantly improved grip strength and diameter of gastrocnemius myocytes, while these parameters were not affected by either treatment alone. Pathway analysis revealed complementary effects of semaglutide and exercise on metabolic, inflammatory and a variety of other pathways, thereby substantiating the added value of combining semaglutide with exercise. Conclusion: Semaglutide has broad beneficial effects on circulating risk factors of metabolic syndrome, liver, vascular and adipose parameters but decreases lean mass and muscle strength. By combining semaglutide intervention with exercise, these parameters are further improved with a partial preservation of lean mass and muscle function.
This dataset
Download
Direct links to NCBI, no account and no request form: the whole study as GSE304862_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 209 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA1303092 and SRA study SRP607365. Searching any of these in the dataset finder brings you back here.
Study design
18 × L.HH vs 14 × L.HHS vs 8 × L.CC
Supports a between-group comparison across 40 samples.
3 replicated groups read from the first 40 of 209 sample titles; they account for 40 of them. Check it against the sample list below before relying on it.
Samples in this study
0 selected
- GSM9158544 L.CC.1
- GSM9158545 L.CC.2
- GSM9158546 L.CC.3
- GSM9158547 L.CC.4
- GSM9158548 L.CC.5
- GSM9158549 L.CC.6
- GSM9158550 L.CC.7
- GSM9158551 L.CC.8
- GSM9158552 L.HH.24
- GSM9158553 L.HH.25
- GSM9158554 L.HH.27
- GSM9158555 L.HH.28
- GSM9158556 L.HH.29
- GSM9158557 L.HH.30
- GSM9158558 L.HH.31
- GSM9158559 L.HH.32
- GSM9158560 L.HH.33
- GSM9158561 L.HH.34
- GSM9158562 L.HH.35
- GSM9158563 L.HH.36
- GSM9158564 L.HH.37
- GSM9158565 L.HH.38
- GSM9158566 L.HHS.39
- GSM9158567 L.HHS.40
- GSM9158568 L.HHS.41
- GSM9158569 L.HHS.42
- GSM9158570 L.HHS.43
- GSM9158571 L.HHS.44
- GSM9158572 L.HHS.45
- GSM9158573 L.HHS.46
- GSM9158574 L.HHS.47
- GSM9158575 L.HHS.49
- GSM9158576 L.HHS.50
- GSM9158577 L.HHS.51
- GSM9158578 L.HHS.52
- GSM9158579 L.HHS.53
- GSM9158580 L.HHR.54
- GSM9158581 L.HHR.55
- GSM9158582 L.HHR.56
- GSM9158583 L.HHR.57
+ 169 more — browse all 209 samples with per-sample file links →
Similar datasets
- GSE326952 Semaglutide-induced Loss of Skeletal Muscle Mass is Blunted by Co-administration of Ketone Esters 13 samples
- GSE338985 Multi-organ proteomic atlas of obesity regression in male mice 94 samples
- GSE334940 Tissue nanotransfection-mediated induction of neurogenic programs promotes myoprotective responses in denervated skeletal muscle 15 samples
- GSE341948 Multi-tissue transcriptomic landscape reveals synergistic mechanisms of exercise and GLP-1 agonist in ameliorating diabetic phenotypes in db/db mice 12 samples
- GSE329539 Hypothalamic transcriptomic response to High-Fat Diet induced obesity: modulatory effects of Resveratrol, Curcumin, and Aged Garlic Extract. 12 samples
- GSE314817 Multi-tissue, multi-time-point transcriptomic atlas of aging in mice and rats [mouse] 2432 samples
- GSE293709 Transcriptome analysis in the prefrontal cortex of different ASD mouse models treated with drug 1565 samples
- GSE294832 Modular neuroinflammatory network discovery from large-scale phenotypic screening in genetically heterogeneous mice [part10] 1000 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.